Will US Government Pursue Fewer False Claims Act Cases In 2019?
Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.
You may also be interested in...
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.
Justice Department lacks absolute right to dismiss meritorious qui tam complaints filed by affiliates of National Healthcare Analysis Group against numerous pharmaceutical companies, whistleblowers say, taking issue with government’s “personal attacks” on their business model and research practices.
Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.